Taken together, our data show that a dynamic decrease in the level of s-IGF-I from the subacute phase to 3 months post-stroke is strongly associated with better stroke outcome at 3 months, whereas the association with outcome at 2 years is weaker. This evidence concerns the gene IGF1 and stroke disorder.